Browse the evidence

Exposure to blue-enriched light (peaking around 460 nm) during daytime hours acts as the strongest synchronizing agent for the human circadian rhythm by suppressing melatonin secretion, thereby enhancing alertness and cognitive performance.

Maximize exposure to bright, blue-enriched natural sunlight or high-quality artificial light during the morning and afternoon to anchor your circadian rhythm and boost daytime alertness. Conversely, minimize exposure to blue-emitting screens (phones, computers) in the 2-3 hours before bedtime to prevent melatonin suppression and sleep onset delays. Use night-mode filters on devices in the evening.

Chronic exposure to blue light at night, particularly from artificial sources like LED screens, disrupts circadian rhythms by suppressing melatonin, leading to sleep onset delays and increased health risks such as breast cancer in shift workers.

If you must use screens at night, use software that removes blue wavelengths (night shift mode) or wear amber-tinted glasses. Prioritize bright morning sunlight to help reset your clock after a night of disrupted light. For shift workers, strategic light exposure (bright light during shift, dark glasses on commute home) is critical.

Low skeletal muscle mass (sarcopenia) is significantly associated with higher insulin resistance, diabetes, and metabolic syndrome in non-obese individuals, particularly those aged 60 and older.

If you are not overweight but are over 60, losing muscle mass puts you at a significantly higher risk for diabetes and metabolic syndrome than if you were overweight. Prioritize resistance training and adequate protein intake to preserve muscle mass, as it acts as a primary site for glucose disposal and metabolic regulation, independent of your body fat levels.

Increasing nitric oxide output has remarkable effects on reducing obesity and improving insulin resistance.

Boosting nitric oxide levels (e.g., through exercise which increases blood flow/shear stress) can help combat obesity and insulin resistance by improving metabolic regulation.

NOS3 (endothelial nitric oxide synthase) has antiobesogenic effects, while NOS2 (inducible nitric oxide synthase) promotes insulin resistance.

Not all nitric oxide is created equal. NOS3 is beneficial for obesity, while NOS2 (often driven by inflammation) worsens insulin resistance. Targeting the right pathway is crucial.

PPARγ ligands (thiazolidinediones) improve systemic insulin sensitivity and lipid profiles in type 2 diabetes by promoting adipocyte differentiation and sequestering free fatty acids into adipose tissue, thereby reducing ectopic lipid accumulation in muscle and liver.

For individuals with type 2 diabetes, PPARγ-activating medications (like TZDs) work by encouraging the body to store fat in adipose tissue rather than in the liver and muscles. This shift reduces insulin resistance and improves blood sugar control, provided the patient has functional fat tissue.

Low-intensity resistance exercise (<50% 1RM) combined with slow movement and tonic force generation produces muscle hypertrophy and strength gains equivalent to high-intensity resistance exercise (~80% 1RM).

To build muscle without lifting heavy weights, use a weight you can lift for 8 repetitions (approx 50% of your max). Perform each repetition slowly: 3 seconds lowering, 3 seconds lifting, and hold the fully extended position for 1 second without relaxing. Do 3 sets, 3 times a week. This creates metabolic stress that triggers growth similar to heavy lifting.

Short-term reduction in daily physical activity (step reduction) induces peripheral insulin resistance and ectopic fat accumulation (liver and visceral adipose tissue) in young, healthy adults within 14 days.

Even if you are young and healthy, dropping your activity level significantly (e.g., from 10,000 to 1,500 steps/day) for just two weeks can cause your body to store fat in the liver and become less sensitive to insulin. This happens even if your total body weight doesn't change. To prevent this, try to maintain your usual activity level or incorporate light movement during periods of reduced activity.

Short-term physical inactivity causes a significant loss of muscle mass (1-4%) in older adults within 14 days, accompanied by anabolic resistance.

If you are over 65, even a short period of reduced activity (like 14 days of low steps) can cause you to lose 1-4% of your muscle mass. This happens because your muscles become less responsive to protein (anabolic resistance). To protect your muscle, try to stay active even if you can't do intense exercise, and ensure you are eating enough protein.

The metabolic and musculoskeletal effects of short-term physical inactivity are reversible in younger adults but less so in older adults.

If you are young, you can likely reverse the negative metabolic and muscle effects of a few weeks of inactivity by returning to your normal routine. If you are older, recovery may be slower and less complete. It is more important for older adults to avoid long periods of inactivity in the first place.

The BodyTime assay, which estimates internal circadian time from a single blood sample using a small set of transcript biomarkers, achieves accuracy comparable to the gold standard dim-light melatonin onset (DLMO) method while being significantly less costly and time-consuming.

If you are interested in optimizing the timing of medications or health interventions (chronotherapeutics), you can now determine your internal circadian phase with a single blood test (BodyTime assay). This test is as accurate as the traditional gold standard (melatonin testing) but is much faster, cheaper, and does not require special lighting conditions. This allows for personalized timing of treatments based on your unique biological clock.

GLP-1 receptor agonists reduce blood pressure and improve lipid profiles (LDL-C, triglycerides), contributing to the stabilization of atherosclerotic plaques and reduced cardiovascular risk.

GLP-1RAs help lower blood pressure and improve cholesterol levels, which protects your arteries from plaque buildup. This is an added benefit beyond blood sugar control, helping to prevent heart attacks and strokes.

GLP-1 receptor agonists exhibit protective effects on the kidneys by reducing the decline in estimated glomerular filtration rate (eGFR) and delaying the onset of proteinuria in patients with Type 2 Diabetes.

GLP-1RAs help protect your kidneys from damage caused by diabetes. They slow down the loss of kidney function and reduce protein leakage into the urine, which is crucial for long-term kidney health.

In obese individuals with chronic short sleep (<6.5 hours/night), an evening chronotype is associated with higher cardiovascular risk, characterized by increased stress hormones (ACTH, epinephrine), higher resting heart rate, and a higher prevalence of sleep apnea compared to morning types.

If you are obese and consistently sleep less than 6.5 hours, being an 'evening person' significantly increases your risk for sleep apnea and stress-related cardiovascular strain. Prioritizing sleep extension and managing evening light exposure may help mitigate these specific hormonal and cardiovascular risks.

Chronic exercise significantly improves sleep quality by increasing total sleep time and reducing time awake after sleep onset, whereas acute exercise effects on slow-wave sleep are inconsistent and depend heavily on timing and intensity.

Prioritize consistent, chronic exercise over specific timing for sleep benefits. While acute effects vary, long-term habitual exercise reliably improves total sleep time and reduces nighttime awakenings. If you exercise late, do not worry excessively about sleep disruption; the body adapts, and quality is often preserved.

PPAR-gamma agonists (thiazolidinediones) reduce liver fat and increase adiponectin levels, whereas metformin does not significantly reduce liver fat content.

If you have fatty liver, standard diabetes medication like metformin may not reduce the liver fat itself, whereas PPAR-gamma agonists (like pioglitazone or rosiglitazone) can significantly reduce it, similar to the effect of moderate weight loss. Consult a doctor for medication options.

Pitolisant (5-20 mg/day) significantly reduces self-reported excessive daytime sleepiness and fatigue in patients with moderate-to-severe obstructive sleep apnea who refuse or are non-adherent to CPAP therapy, without improving objective maintenance of wakefulness.

If you have moderate to severe sleep apnea but cannot or will not use CPAP, pitolisant (5-20mg daily) can significantly reduce your daytime sleepiness and fatigue. It does not fix the breathing pauses or objectively improve your ability to stay awake in a lab test, but it does make you feel less sleepy and improves your quality of life. It is generally safe with side effects similar to placebo.

Exercise acts as a non-pharmacological intervention that counteracts age-related insulin resistance by enhancing mitochondrial oxidative capacity, improving autophagy, and reducing oxidative stress and inflammation.

Regular exercise is one of the most effective ways to combat age-related insulin resistance. It improves your muscles' ability to use energy, clears out cellular waste, and reduces inflammation, keeping your insulin sensitivity high.

Testosterone treatment in older men with low testosterone improves walking distance and perceived mobility, although the effect on slow walkers is small.

Testosterone therapy may slightly improve your walking distance and perceived mobility, especially if you are not a slow walker. The effect is small, but it may still be clinically important for maintaining independence. The treatment involves daily application of a gel, with dose adjustments to keep levels in the normal range for young men.

Metformin therapy improves menstrual function and ovulation rates in PCOS patients, with efficacy varying based on baseline testosterone levels and severity of menstrual irregularities.

Metformin is an effective medication for restoring regular periods and ovulation in many PCOS patients, working in 40-90% of cases. It is often used when lifestyle changes alone are insufficient or for fertility treatment. Discuss with your doctor if it's right for you, as it may cause stomach upset initially.

Female overweight (BMI 25-29), obesity (BMI 30-34), and very obesity (BMI >=35) are associated with significantly reduced fecundability (longer time-to-pregnancy) compared to normal weight women, with the association strengthening when central adiposity (waist circumference) is controlled for.

If you are trying to conceive and have a BMI in the overweight or obese range, your time-to-pregnancy may be significantly longer than if you were normal weight. This effect is even stronger if you carry excess weight around your waist. While weight loss is not a guaranteed fix, maintaining a healthy weight may improve your chances of conceiving naturally within a typical timeframe.

Weight gain of 15 kg or more since age 17 is associated with reduced fecundability (longer time-to-pregnancy), independent of current BMI at age 17.

If you have gained 15 kg or more since your late teens, your ability to conceive may be reduced, even if your current weight is within a 'normal' range. This suggests that the process of weight gain itself, or the metabolic changes it brings, can impact fertility.

Prolonged physical inactivity combined with chronic hypercortisolemia (simulating clinical stress/illness) causes significantly greater loss of lean muscle mass and strength than inactivity alone, driven primarily by a chronic reduction in muscle protein synthesis rather than increased breakdown.

If you are recovering from an injury or illness requiring bed rest, your body's stress hormones (cortisol) will significantly accelerate muscle loss by shutting down protein synthesis. This loss is worse than inactivity alone. While you cannot always avoid the need for rest, recognizing this mechanism highlights the importance of medical interventions that support protein synthesis during recovery, rather than assuming muscle loss is inevitable.

Exogenous melatonin advances sleep-wake rhythm and endogenous melatonin onset in patients with Delayed Sleep Phase Disorder (DSPD) when administered chronobiologically timed (approximately 5 hours prior to Dim Light Melatonin Onset).

For individuals with DSPD, taking melatonin approximately 5 hours before their natural sleep onset time (DLMO) effectively shifts their internal clock earlier, leading to earlier sleep onset and advanced melatonin production. This requires identifying one's natural melatonin onset time.